Essex Bio-Technology (01061) has announced that on August 24, 2026, it allocated HK$90,600 to buy back 40,000 of its own shares.
This repurchase move reflects the company's ongoing capital management strategy, aimed at enhancing shareholder value through the reduction of outstanding shares in the market.
The transaction was executed on the open market, with the total expenditure for the buyback amounting to approximately HK$90,600.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments